<DOC>
	<DOCNO>NCT01472926</DOCNO>
	<brief_summary>A pilot evaluation tenecteplase compare alteplase acute ischaemic stroke patient currently eligible intravenous alteplase treatment prospective , randomise , blind outcome evaluation clinical trial use brain imaging biomarker .</brief_summary>
	<brief_title>Alteplase-Tenecteplase Trial Evaluation Stroke Thrombolysis- ( ATTEST )</brief_title>
	<detailed_description>Newer thrombolytic agent tenecteplase pharmacological feature ( high fibrin bind specificity longer half-life ) may advantageous compare old agent alteplase respect arterial recanalisation , ease administration , reduce bleeding risk . No clinical trial currently evaluate alternative thrombolytic strategy patient eligible receive standard intravenous alteplase , instead concentrate extend population IV thrombolysis . The ATTEST pilot phase use brain imaging biomarker key clinical response variable , penumbral salvage primary end-point secondary end-points include recanalisation well conventional clinical scale . The finding study anticipate provide data sample size event rate inform design definitive , confirmatory , pragmatic , randomise , control trial clinical endpoint .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<mesh_term>Tenecteplase</mesh_term>
	<criteria>clinical diagnosis supratentorial acute ischaemic stroke score least 1 NIH Stroke Scale male non pregnant female &gt; =18 year within 4.5 hour onset defined time since last know well CT perfusion CT Angiogram examination acquire prior treatment Contraindications thrombolytic drug treatment stroke Evidence intracranial haemorrhage significant nonstroke intracranial pathology ( include central nervous system neoplasm , aneurysm arteriovenous malformation ) pretreatment CT Established hypodensity pretreatment brain CT one third middle cerebral artery territory Alberta Stroke Programme Early CT ( ASPECT ) Score &lt; 4 ( sulcal effacement loss greywhite differentiation cortical territory alone count towards ASPECT score ) Hypodensity consistent recent cerebral ischaemia present event Very severe stroke ( eg NIHSS &gt; 25 ) systolic blood pressure ( BP ) &gt; 185 diastolic BP &gt; 110 mm Hg , aggressive management ( intravenous pharmacotherapy ) necessary reduce BP limit If warfarin , International Normalised Ratio ( INR ) &lt; 1.4 Current prescription nonwarfarin oral anticoagulant drug Significant abnormality coagulation parameter pretreatment ( prolonged INR activate partial thromboplastin time ( APTT ) , platelet count &lt; 100,000/mm3 ) administration heparin within previous 48 hour thromboplastin time exceed upper limit normal laboratory , use therapeutic dose low molecular weight heparin within 48h Clinical history suggestive subarachnoid haemorrhage even blood evident CT Risk bleeding ( Major surgery within previous 1 month ; intracranial spinal surgery ; recent trauma head cranium ; prolong cardiopulmonary resuscitation ( &gt; 2 minute ) within past 2 week ; acute pericarditis and/or subacute bacterial endocarditis ; acute pancreatitis ; severe hepatic dysfunction , include hepatic failure , cirrhosis , portal hypertension ( oesophageal varix ) active hepatitis ; active peptic ulceration ; know history haemorrhagic stroke stroke unknown origin ; arterial aneurysm know arteriovenous malformation ) Dependent ( mRS 35 ) prestroke Blood glucose &lt; 2 mmol/l &gt; 18 mmol/l Seizure onset symptom unless brain imaging identifies positive evidence significant brain ischaemia ( eg CTA confirm arterial occlusion , early ischaemic change plain CT , hypoperfusion CTP ) Pregnancy Known impair renal function ( estimate Glomerular Filtration Rate &lt; 30 ml/min ) preclude contrast CT Known allergy radiological contrast History allergy active substance either trial medication , excipients include gentamicin Severe concurrent medical condition would prevent participation study procedure ( e.g . cardia failure severe pulmonary oedema ) life expectancy &lt; =3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>acute ischaemic stroke</keyword>
	<keyword>stroke</keyword>
	<keyword>thrombolysis</keyword>
	<keyword>thrombolytic drug therapy</keyword>
	<keyword>CT perfusion</keyword>
	<keyword>CT angiography</keyword>
	<keyword>brain imaging</keyword>
</DOC>